Oragenics Inc (OGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oragenics Inc (OGEN) has a cash flow conversion efficiency ratio of -0.356x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.20 Million) by net assets ($6.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Oragenics Inc market capitalisation for the company's overall valuation and market capitalisation.
Oragenics Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Oragenics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oragenics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oragenics Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Oragenics Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SRT Marine Systems plc
LSE:SRT
|
-0.305x |
|
Rocky Mountain Liquor Inc
V:RUM
|
0.030x |
|
GENERIC GOLD CORP.
F:1WD
|
N/A |
|
Blue Star Capital plc
LSE:BLU
|
-0.049x |
|
Performance One AG
F:PO1
|
N/A |
|
Nanocap Group AB Series B
ST:NANOC-B
|
N/A |
|
Newpeak Metals Ltd
AU:NPM
|
-0.132x |
|
Neurizer Ltd
AU:NRZ
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Oragenics Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of Oragenics Inc from 2003 to 2025. View OGEN share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.28 Million | $-9.25 Billion | -1116.524x | -2851.71% |
| 2024-12-31 | $-211.88K | $-8.60 Million | 40.576x | +1863.16% |
| 2023-12-31 | $3.17 Million | $-7.29 Million | -2.301x | -96.59% |
| 2022-12-31 | $13.01 Million | $-15.23 Million | -1.171x | -130.17% |
| 2021-12-31 | $26.49 Million | $-13.47 Million | -0.509x | +49.47% |
| 2020-12-31 | $16.84 Million | $-16.95 Million | -1.006x | -33.27% |
| 2019-12-31 | $17.23 Million | $-13.01 Million | -0.755x | -73.68% |
| 2018-12-31 | $20.88 Million | $-9.08 Million | -0.435x | +56.84% |
| 2017-12-31 | $6.32 Million | $-6.36 Million | -1.008x | +57.77% |
| 2016-12-31 | $2.97 Million | $-7.08 Million | -2.386x | -121.11% |
| 2015-12-31 | $4.73 Million | $-5.10 Million | -1.079x | -100.60% |
| 2014-12-31 | $10.34 Million | $-5.56 Million | -0.538x | -25.93% |
| 2013-12-31 | $15.84 Million | $-6.76 Million | -0.427x | +24.35% |
| 2012-12-31 | $9.23 Million | $-5.21 Million | -0.565x | -184.04% |
| 2011-12-31 | $-8.18 Million | $-5.49 Million | 0.672x | -80.21% |
| 2010-12-31 | $-1.90 Million | $-6.45 Million | 3.395x | +254.53% |
| 2009-12-31 | $2.64 Million | $-5.80 Million | -2.197x | -110.15% |
| 2008-12-31 | $-177.25K | $-3.84 Million | 21.637x | +1026.98% |
| 2007-12-31 | $819.88K | $-1.91 Million | -2.334x | -34.13% |
| 2006-12-31 | $1.28 Million | $-2.22 Million | -1.740x | +10.23% |
| 2005-12-31 | $1.77 Million | $-3.43 Million | -1.939x | -185.04% |
| 2004-12-31 | $4.04 Million | $-2.75 Million | -0.680x | -91.94% |
| 2003-12-31 | $3.44 Million | $-1.22 Million | -0.354x | -- |
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation w… Read more